Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.1 USD | -0.41% | -0.04% | -14.85% |
Financials (USD)
Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 15.59B |
---|---|---|---|---|---|
Net income 2024 * | 359M | Net income 2025 * | 495M | EV / Sales 2024 * | 5.44 x |
Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.62 x |
P/E ratio 2024 * |
45.3
x | P/E ratio 2025 * |
32.2
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | -0.41% | ||
1 week | -0.04% | ||
Current month | +1.66% | ||
1 month | -5.58% | ||
3 months | -8.57% | ||
6 months | +7.71% | ||
Current year | -14.85% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | -4.80% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 82.1 | -0.41% | 895,206 |
24-05-03 | 82.44 | -1.62% | 1,632,894 |
24-05-02 | 83.8 | +0.56% | 1,221,297 |
24-05-01 | 83.33 | +3.18% | 1,881,895 |
24-04-30 | 80.76 | -1.67% | 2,018,244 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.85% | 15.59B | |
-2.47% | 88.14B | |
+1.45% | 40.44B | |
-14.43% | 32.24B | |
+52.60% | 24.39B | |
-13.87% | 12.14B | |
-7.87% | 12.18B | |
-39.40% | 12.3B | |
+5.62% | 8.87B | |
-6.78% | 8.41B |
- Stock Market
- Equities
- BMRN Stock